All In Biotech

Investigational drug · Phase 3

Gen 2 Travoprost Intracameral Implant

Also called: Gen 2 Travoprost Intraocular Implant

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glaucoma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "Gen 2 Travoprost Intracameral Implant"

First trial start

2025

Jun 12, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Gen 2 Travoprost Intracameral Implant", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Glaucoma

Approved drugs for the same conditions: Glaucoma · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "Gen 2 Travoprost Intracameral Implant" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Glaucoma

  • SpyGlass Pharma, Inc. · Cataract, Glaucoma, Ocular Hypertension

  • Timolol eye drops 0.5%Phase 33 trials

    Glaukos Corporation · Glaucoma, Ocular Hypertension

  • Inactive controlQLS-111 vehiclePhase 32 trials

    Can-Fite BioPharma · Hepatocellular Carcinoma, Cirrhosis, Open-angle Glaucoma (OAG)

  • QLS-111Phase 23 trials

    Qlaris Bio, Inc. · Normal Tension Glaucoma (NTG), Glaucoma, Open-angle Glaucoma (OAG)

  • BL1107Phase 22 trials

    Bausch & Lomb Incorporated · Dry Eye Disease, Glaucoma

  • ASP2767Phase 21 trial

    Astellas · Glaucoma

  • intraocular implant releasing timololTimoD implantPhase 21 trial

    EyeD Pharma · Glaucoma, Ocular Hypertension

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.